Evidence Framework transformation of a global medical-device regulatory function

Institutional Context

A global manufacturer and distributor of medical devices, diagnostic equipment, and healthcare IT platforms. The regulatory affairs function reports to the Chief Regulatory Officer; the GC maintains a formal interface for AI-governance matters.

The function regulatory perimeter spans FDA (US), the EU Medical Device Regulation and In-Vitro Diagnostic Regulation (EU MDR / IVDR), ISO 13485 (Quality Management Systems — Medical Devices), ISO 14971 (Risk Management — Medical Devices), HIPAA, GDPR, and approximately forty country-specific medical-device regimes.

Operating cadence pre-AI

Compliance documentation review against regulatory requirements took 6–8 weeks per product launch, with a 12% error rate in initial compliance submissions. Submission preparation (510(k), CE Mark, international country-specific) took 4–6 weeks of senior-specialist time per product.

Regulatory-change monitoring across 15 regulatory bodies plus 200+ annual updates was manual, with an average 6-week lag between regulation publication and impact assessment. The function reported approximately 8,200 active regulatory documents and 14,000 product compliance files distributed across seven storage systems.

The institutional bind

The function maintained an established ISO 13485 QMS that had passed multiple FDA inspections without observation. The bind is canonical for the Evidence Framework archetype: the function had a mature QMS — including risk management per ISO 14971, validated electronic systems per 21 CFR Part 11, and document control per ISO 13485 — but had no extension of that QMS to absorb AI-assisted regulatory operations. AI tools introduced into this environment would have to comply with the existing QMS, not run alongside it.

Operational Friction

Compliance documentation review consumed 6–8 weeks per product launch; submission preparation 4–6 weeks of senior-specialist time; 12% error rate in initial submissions traced to manual cross-referencing.

The proximate trigger

The CEO mandate to the Chief Regulatory Officer in 2024-Q4 required a 50% reduction in regulatory review cycles within 18 months to support the company emerging-market growth strategy. Traditional approaches — hiring eight additional regulatory specialists — were untenable: the talent market was constrained, six-month ramp times would not deliver against the strategic horizon.

The systemic friction

Per-week launch-delay revenue impact was $1.2M for flagship products. Competitors with faster regulatory processes were capturing first-mover advantage in two of four most-recent emerging-market clearances. Specialists with PhDs in regulatory science were spending 40% of their time on administrative cross-referencing.

The systemic friction was the operating-model gap: an established QMS with no AI-extension framework cannot deliver the velocity the strategy required.

Strategic Imperative

The CEO mandate to the CRO was specific and instrumented: a 50% reduction in regulatory review cycles, while preserving the function existing QMS posture and its FDA inspection record. Traditional approaches were untenable; the talent market was constrained and six-month ramp times could not deliver against the strategic horizon.

“Either we built an AI-extension to our QMS that absorbed AI-assisted regulatory operations under the same validation discipline we already applied to medical-device software, or we ceded the first-mover advantage in emerging markets to faster-regulating competitors. The first choice required the QMS to grow.”

— Chief Regulatory Officer (anonymised)· 1 November 2024

Legal AI OS Transformation Thesis

This case is the canonical Evidence Framework archetype. The function did not adopt AI into greenfield governance; the function adopted AI into a mature ISO 13485 quality management system that had passed multiple FDA inspections without observation.

QMS extension, not parallel committee

The transformation thesis is one of QMS extension. The existing Risk Register (ISO 14971-aligned), the existing electronic-records architecture (21 CFR Part 11), the existing supplier evaluation process (ISO 13485 §7.4), and the existing change-control procedure (ISO 13485 §4.2.4) were all extended to absorb AI-assisted regulatory operations as a new class of validated software within the QMS scope.

The Defensibility framework operationalises naturally in this archetype. ISO 13485 already requires document control, validation, calibration, and continuous improvement; the Evidence Register is a natural extension of the QMS document control framework. The Defensibility Posture Statement is a natural extension of management review (ISO 13485 §5.6).

The Maturity Stack arc

The Maturity Stack movement from Operational to Optimised reflects the function transition from a QMS that produces regulatory submissions to a QMS that produces regulatory submissions with an AI-extension that is itself validated, audited, and continuously evaluated within the same governance frame.

Maturity Stack Progression

The function operated established document-management automation but had no integrated AI strategy. Defensibility was elevated relative to Adoption and Sophistication because the underlying QMS — independently of AI — already maintained validated electronic records, decision audit trails for regulatory submissions, and a quarterly management-review cadence. The function had a Risk Register (ISO 14971-aligned) but no Evidence Register specific to AI. The function had no AI Operating Policy. The function had no named accountable owner for AI use.

Human & Organisational Impact

The function pre-engagement composition skewed toward deep tenure: average regulatory specialist tenure of 14 years; multiple specialists with PhDs in regulatory science. The engagement assumption — that senior specialists would resist AI most strongly — was inverted.

Senior expertise as the validation surface

Senior specialists, with two decades of regulatory experience, became the most effective validators of AI outputs because their domain knowledge allowed them to validate edge cases at AI speed. Adoption among 15-plus-year-tenure professionals reached 89% within twelve months, the highest of any tenure cohort.

One Vice President of Regulatory Affairs, with 35 years of experience, became the engagement most consequential advocate; her transition is the canonical Evidence Framework adoption pattern.

Role evolution

Three roles evolved through the engagement:

• ●Senior Regulatory Specialist — pre-engagement role of monitoring + drafting; post-engagement role of validation + strategic regulatory engagement
• ●Regulatory Affairs Manager — pre-engagement role of resource allocation; post-engagement role of operating-model design (per-jurisdiction AI calibration, escalation paths, evidence framework maintenance)
• ●Regulatory Analyst (newly designated) — post-engagement role of AI-flagged remediation tracking and Evidence Register maintenance

Time-allocation shift: pre-engagement, specialists spent 40% of time on administrative tasks; post-engagement, 12%. Strategic regulatory work expanded from 25% to 55% of specialist time. Job satisfaction (Likert 1–10) moved from 7.1 to 8.6. No attrition was recorded as AI-related.

Risk & Governance Framework

Integration into ISO 13485 Management Review

AI governance is integrated into the existing ISO 13485 Management Review (ISO 13485 §5.6), not run as a parallel committee. The Management Review reviews, at quarterly cadence: AI accuracy metrics, AI-flagged regulatory changes, AI-incident counts, vendor performance against SLAs, Evidence Register completeness, Defensibility Posture Statement maturity.

Membership: CRO (chair), GC, Quality Director, Head of R&D, CFO. Outputs are QMS-controlled records.

Defensibility Posture Statement at quarterly cadence

Defensibility Posture Statement is in place at quarterly cadence, integrated into QMS Management Review. Signed by the CRO. Reviewed by the GC and the Quality Director before signature. Producible within twenty-four hours of any external request. Specifically tested at the engagement-window FDA inspection — produced within four hours of inspector request, with the inspector subsequently commending the approach.

Escalation paths

Documented for five scenarios:

• ●AI-related quality event — first responder: Quality Director; escalation to CRO + CEO
• ●AI-related regulatory finding — first responder: Senior Regulatory Specialist (named per submission); escalation path to FDA pre-submission disclosure protocol where applicable
• ●AI-related data-protection event — first responder: IT Security Director; GDPR / BAA notification protocol
• ●AI accuracy degradation below quarterly validation threshold — first responder: vendor account manager; recalibration trigger
• ●Vendor service disruption — first responder: Product Compliance Manager; documented manual-fallback procedure

Board reporting

The function reports to the CEO at quarterly cadence on regulatory velocity (cycle times by product line), AI accuracy metrics, regulatory submission success rates, and audit findings. The report is the institutional substrate the CEO reads against and is the basis for the quarterly board update.